Abstract
To improve the results of hepatectomy in cirrhotic patients, the likely reserve function of the liver was evaluated before surgery. Asialoglycoprotein receptor (ASGP-R) is a hepatic cell surface receptor specific for galactose-terminated glycoproteins. Technetium-99m-diethylene triamine pentaacetic acid-galactosyl human serum albumin (99mTc-GSA) is a newly developed analog ligand to ASPG-R. The probable functional reserve of the remnant liver after hepatectomy was estimated preoperatively as the hepatic binding protein (HBP) concentration specific for ASGP-R on the hepatocellular membrane of the remnant liver. This estimate was based on the effective liver volume rate, obtained by the uptake of99mTc-GSA. In all, 3 normal volunteers, 3 patients with chronic hepatitis (CH), 9 patients with liver cirrhosis (LC), 2 patients with hepatic cystadenoma, 3 patients with hepatocellular carcinoma (HCC) associated with CH, and 21 HCC patients with LC were studied. The mean value ±SD obtained for HBP in normal volunteers (three cases) and in patients with mild (four cases), moderate (two cases), and severe liver damage (five cases) were 0.74±0.03 μM, 0.43±0.042 μM, 0.31±0.05 μM, and 0.20±0.05 μM, respectively. Most of the cases in which the preoperative HBP of the remnant liver was above 0.22 μM had a good postoperative course irrespective of the type of hepatectomy. On the other hand, in subjects with a remnant liver HBP of between 0.22 and 0.11 μM, postoperative severe liver dysfunction occurred in about 50% of cases. In all cases with a remnant liver HBP below 0.1 μM, the prognosis was very poor, indicating that hepatectomy should be avoided. The HBP concentration detected by the99mTc-GSA study is a very sensitive indicator of changes in the hepatic functional reserve, and the HBP value for the functional reserve of the remnant liver is extremely useful for estimating the liver function before and after hepatectomy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ashwell G, Steer CJ (1981) Hepatic recognition and catabolism of serum glycoproteins. JAMA 246: 2358
Gartner U, Stockert RJ, Morell AG, Wolkoff AW (1981) Modulation of the transport of bilirubin and asialoorosomucoid during liver regeneration. Hepatology 1: 99
Kudo M, Vera DR, Stadalnik RC, Trudeau WL, Ikekubo K, Todo A (1990) In vivo estimates of hepatic binding concentration: correlation with classical indicator of hepatic functional reserve. Am J Gastroenterol 85: 1142
Kudo M, Vera DR, Trudeau WL, Stadalnik RC (1991) Validation of in vivo receptor measurements via in vitro radioassay: technetium-99m-galactosyl-neoglycoalbumin as a prototype model. J Nucl Med 32: 1177
Kudo M, Todo A, Ikekubo K, Hino M, Yonekura Y, Yamamoto K, Torizuka K (1991) Functional hepatic imaging with receptorbinding radiopharmaceutical: clinical potential as a measure of functional hepatocyte mass. Gastroenterol Jpn 26: 734
Lee YC, Stowell CP, Krantz MJ (1976) 2-Imino-2-methoxyethyl-1-thioglycosides: new reagents for attaching sugars to proteins. Biochemistry 15: 3956
Moody FG, Rikkers LF, Aldrete JS (1974) Estimation of the functional reserve of human liver. Ann Surg 180: 592
Noguchi T, Imai T, Mizuno R (1990) Preoperative estimation of surgical risk of hepatectomy in cirrhotic patients. Hepatogastroenterology 37: 165
Paumgartner G, Probst GP, Kraines R, Leevy CM (1970) Kinetics of indocyanine green removal from the blood. Ann NY Acad Sci 170: 134
Stadalnik RC, Vera DR, Woodle S, Trudeau WL, Porter BA, Ward RE, Krohn KA, O'Grady LF (1985) Technetium-99m-NGA functional hepatic imaging: preliminary clinical experience. J Nucl Med 26: 1233
Stockert RJ, Morell AG (1983) Hepatic binding protein: The galactose-specific receptor of mammalian hepatocytes. Hepatology 3: 750
Torizuka K, Ha-Kawa SK, Kudo M, Kubota Y, Yamamoto K, Itoh K, Nagao K, Uchiyama G, Koizumi K, Sasaki Y, Kosaka N, Murata H, Murashima N, Kosuda S, Suzuki K, Ishii K, Imaeda T, Kanematsu M, Nakamura K, Nakagawa T, Hisada K, Aburano T, Nakajima T, Ishii Y, Morita R, Suzuki T, Kubo S, Konishi J, Ohishi H, Imai T, Tanaka Y, Kitagawa S, Inoue K, Kashiwagi T, Kozuka T, Shiomi S, Ochi H, Hasegawa Y, Sasaki Y, Ikekubo K, Hino M, Niiya H, Hiraki Y, Tanabe M, Kawasaki Y, Tsuda T, Hamamoto K, Masuda K, Ichiya Y (1992) Phase III multi-center clinical study on99mTc-GSA, a new agent for functional imaging of the liver. Jpn J Nucl Med 29: 159
Vera DR, Stadalnik RC, Krohn KA (1985) Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studies. J Nucl Med 26: 1157
Vera DR, Krohn KA, Scheibe PO, Stadalnik RC (1985) Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Eng 32: 312
Vera DR, stadalnik RC, Trudeau WL, Scheibe PO, Krohn KA (1991) Measurement of receptor concentration and forward binding rate constant via radiopharmacokinetic modeling of technetium-99m-galactosyl-neoglycoalbumin. J Nucl Med 32: 1169
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yumoto, Y., Umeda, M., Ohshima, K. et al. Estimation of remnant liver function before hepatectomy by means of technetium-99m-diethylenetriamine-pentaacetic acid galactosyl human albumin. Cancer Chemother. Pharmacol. 33 (Suppl 1), S1–S6 (1994). https://doi.org/10.1007/BF00686659
Issue Date:
DOI: https://doi.org/10.1007/BF00686659